131 related articles for article (PubMed ID: 23231541)
1. Novel methods and strategies in the discovery of TACE inhibitors.
Murumkar PR; Giridhar R; Yadav MR
Expert Opin Drug Discov; 2013 Feb; 8(2):157-81. PubMed ID: 23231541
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
3. Novel TACE inhibitors in drug discovery: a review of patented compounds.
Murumkar PR; DasGupta S; Chandani SR; Giridhar R; Yadav MR
Expert Opin Ther Pat; 2010 Jan; 20(1):31-57. PubMed ID: 20021284
[TBL] [Abstract][Full Text] [Related]
4. Current perspective of TACE inhibitors: a review.
DasGupta S; Murumkar PR; Giridhar R; Yadav MR
Bioorg Med Chem; 2009 Jan; 17(2):444-59. PubMed ID: 19095454
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
6. Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats.
Matsumoto H; Koga H; Iida M; Tarumi K; Fujita M; Haruma K
Scand J Gastroenterol; 2006 Nov; 41(11):1320-9. PubMed ID: 17060126
[TBL] [Abstract][Full Text] [Related]
7. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
Wu D; Gu Q; Zhao N; Xia F; Li Z
J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
[TBL] [Abstract][Full Text] [Related]
8. The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.
Rosner KE; Guo Z; Orth P; Shipps GW; Belanger DB; Chan TY; Curran PJ; Dai C; Deng Y; Girijavallabhan VM; Hong L; Lavey BJ; Lee JF; Li D; Liu Z; Popovici-Muller J; Ting PC; Vaccaro H; Wang L; Wang T; Yu W; Zhou G; Niu X; Sun J; Kozlowski JA; Lundell DJ; Madison V; McKittrick B; Piwinski JJ; Shih NY; Arshad Siddiqui M; Strickland CO
Bioorg Med Chem Lett; 2010 Feb; 20(3):1189-93. PubMed ID: 20022498
[TBL] [Abstract][Full Text] [Related]
9. Conversion of potent MMP inhibitors into selective TACE inhibitors.
Cherney RJ; King BW; Gilmore JL; Liu RQ; Covington MB; Duan JJ; Decicco CP
Bioorg Med Chem Lett; 2006 Feb; 16(4):1028-31. PubMed ID: 16289878
[TBL] [Abstract][Full Text] [Related]
10. Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity.
Solomon A; Rosenblum G; Gonzales PE; Leonard JD; Mobashery S; Milla ME; Sagi I
J Biol Chem; 2004 Jul; 279(30):31646-54. PubMed ID: 15102849
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Sheppeck JE; Gilmore JL; Yang A; Chen XT; Xue CB; Roderick J; Liu RQ; Covington MB; Decicco CP; Duan JJ
Bioorg Med Chem Lett; 2007 Mar; 17(5):1413-7. PubMed ID: 17188863
[TBL] [Abstract][Full Text] [Related]
12. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.
Sarkate AP; Murumkar PR; Lokwani DK; Kandhare AD; Bodhankar SL; Shinde DB; Bothara KG
SAR QSAR Environ Res; 2015; 26(11):905-23. PubMed ID: 26588187
[TBL] [Abstract][Full Text] [Related]
13. Recent developments and strategies for the discovery of TACE inhibitors.
Murumkar PR; Ghuge RB; Chauhan M; Barot RR; Sorathiya S; Choudhary KM; Joshi KD; Yadav MR
Expert Opin Drug Discov; 2020 Jul; 15(7):779-801. PubMed ID: 32281878
[TBL] [Abstract][Full Text] [Related]
14. Prediction of novel and selective TNF-alpha converting enzyme (TACE) inhibitors and characterization of correlative molecular descriptors by machine learning approaches.
Cong Y; Yang XG; Lv W; Xue Y
J Mol Graph Model; 2009 Oct; 28(3):236-44. PubMed ID: 19729328
[TBL] [Abstract][Full Text] [Related]
15. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling and biological effects of peptidomimetic inhibitors of TACE activity.
Feng WF; Zhao YB; Huang W; Yang YZ
J Enzyme Inhib Med Chem; 2010 Aug; 25(4):459-66. PubMed ID: 19951006
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.
Mazzola RD; Zhu Z; Sinning L; McKittrick B; Lavey B; Spitler J; Kozlowski J; Neng-Yang S; Zhou G; Guo Z; Orth P; Madison V; Sun J; Lundell D; Niu X
Bioorg Med Chem Lett; 2008 Nov; 18(21):5809-14. PubMed ID: 18835710
[TBL] [Abstract][Full Text] [Related]
18. Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.
Yang JS; Chun K; Park JE; Cho M; Seo J; Song D; Yoon H; Park CH; Joe BY; Choi JH; Kim MH; Han G
Bioorg Med Chem; 2010 Dec; 18(24):8618-29. PubMed ID: 21078557
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling for the identification of small-molecule inhibitors of TACE.
Liu LJ; Leung KH; Lin S; Chan DS; Susanti D; Rao W; Chan PW; Ma DL; Leung CH
Methods; 2015 Jan; 71():92-7. PubMed ID: 25260600
[TBL] [Abstract][Full Text] [Related]
20. Discovery and SAR of hydantoin TACE inhibitors.
Yu W; Guo Z; Orth P; Madison V; Chen L; Dai C; Feltz RJ; Girijavallabhan VM; Kim SH; Kozlowski JA; Lavey BJ; Li D; Lundell D; Niu X; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Sun J; Tong L; Umland S; Wong MK; Yang DY; Zhou G
Bioorg Med Chem Lett; 2010 Mar; 20(6):1877-80. PubMed ID: 20172725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
